Edesa Biotech, Inc.EDSA

Market cap
$35.96M
P/E ratio
Sep 30,
2015
Sep 30,
2016
Sep 30,
2017
Sep 30,
2018
Sep 30,
2020
Sep 30,
2021
Sep 30,
2022
Sep 30,
2023
Sep 30,
2024
Research and development12223181353
General and administrative333336544
Loss from operations--4,908,356-5,224,546-5,078,250-6,400,842-23,681,332-18,370,790-9,222,758-7,014,744
Reimbursement grant income--------698,277
Interest income-----11,16563,523289,846153,498
Misc other income--------14,766
Foreign exchange loss-653,33376,800162,028-35,059-366--21,114-21,742-21,042
Nonoperating Income (Expense)2-110,524194,69840,10137,41210-849,143845,499
Loss before income taxes-------17,548,124-8,373,615-6,169,245
Income tax expense36,8007,200800800800800800800800
Net loss-2,843,029-5,026,080-5,030,648-5,038,949-6,364,230-13,342,350188-6
Exchange differences on translation----54,87081,942--1,046-27,965
Net comprehensive loss-----6,309,360-13,261,208-17,557,264-8,375,461-6
Loss per common share - basic and diluted (in dollars per share)-0.36-0.57-------1.93